Thu, May 29, 8:38 PM (22 days ago)
### Summary of STERIS plc (STE) Financial Performance **Revenue:** $5,459.5 million for the fiscal year ended March 31, 2025, up 6.2% from $5,138.7 million in 2024. This growth was driven by higher volume and pricing across all segments. **Net Income:** $616.1 million for the fiscal year ended March 31, 2025, up from $380.1 million in 2024. This increase was primarily due to higher volume and pricing, partially offset by legal costs and a settlement associated with EO litigation, increased labor costs, and higher restructuring expenses. **Earnings Per Share (EPS):** $6.24 for the fiscal year ended March 31, 2025, up from $3.83 in 2024. **Operating Expenses:** $1,536.1 million for the fiscal year ended March 31, 2025, up 11.1% from $1,382.0 million in 2024. This increase was primarily due to higher compensation and benefit costs, as well as legal costs associated with EO litigation. **Capital Expenditures:** $370.1 million for the fiscal year ended March 31, 2025, up from $360.3 million in 2024. The company plans to continue investing in facility expansions and ongoing maintenance for existing facilities. **Debt:** As of March 31, 2025, STERIS had approximately $2,043.7 million of indebtedness outstanding, which included $1,350.0 million of Senior Public Notes issued April 1, 2021, $674.2 million of Private Placement Senior Notes, and $34.8 million of borrowings outstanding under the Revolving Credit Facility. **Market Position:** STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company operates in three reportable business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. **Risk Factors:** The company faces various risks, including legal, regulatory, and tax risks, as well as business and operational risks. These risks include changes in economic climate, compliance with multiple international laws, supply chain disruption, and cybersecurity threats. **Future Outlook:** STERIS expects to manage costs, grow its business with internal product and service development, invest in greater capacity, and augment these value-creating methods with potential acquisitions of additional products and services. **Financial Condition:** The company's debt-to-total capital ratio was 23.6% at March 31, 2025. STERIS has paid quarterly dividends each year since 2005 and has increased the dividend each consecutive year, including an increase during fiscal 2025 to $0.57 per share. **Market for Registrant's Ordinary Equity:** As of March 31, 2025, there were approximately 373 holders of record of the company's ordinary shares. The company's ordinary shares are traded on the New York Stock Exchange under the symbol "STE." **Share Repurchase Program:** On May 3, 2023, the Board of Directors authorized a new share repurchase program for the purchase of up to $500.0 million (exclusive of fees, commissions, and other charges), which has no specified expiration date. As of March 31, 2025, there was $300.0 million (exclusive of fees, commissions, and other charges) of remaining availability under the Board authorized share repurchase program.